Abstract:BACKGROUND:Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD). The molecular mechanism underlying the pathogenic role of LRRK2 mutations in PD remains unknown.METHODOLOGY/PRINCIPAL FINDINGS:Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain. We identified multiple phosphorylation sites at N-terminus of LRRK2 including S910, S912, S935 and S973. Focusing on the high stoichiometry S935 phosphorylation site, we developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice. We find that 14-3-3 proteins (especially isoforms γ and η) bind LRRK2 and this binding depends on phosphorylation of S935. The binding of 14-3-3, with little effect on dimer formation of LRRK2, confers protection of the phosphorylation status of S935. Furthermore, we show that protein kinase A (PKA), but not LRRK2 kinase itself, can cause the phosphorylation of LRRK2 at S935 in vitro and in cell culture, suggesting that PKA is a potential upstream kinase that regulates LRRK2 function. Finally, our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.CONCLUSIONS/SIGNIFICANCE:LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-mediated cellular functions. Our study suggests that PKA, a cAMP-dependent kinase involved in regulating dopamine physiology, is a potential upstream kinase that phosphorylates LRRK2 at S935. Furthermore, the reduction of phosphorylation/14-3-3 binding of LRRK2 due to the common familial PD-related mutations provides novel insight into the pathogenic mechanism of LRRK2-linked PD.

How Parkinson's Disease-Related Mutations Disrupt the Dimerization of WD40 Domain in LRRK2: a Comparative Molecular Dynamics Simulation Study

The Wd40 Domain Is Required For Lrrk2 Neurotoxicity

Structural Model of the Dimeric Parkinson'S Protein Lrrk2 Reveals A Compact Architecture Involving Distant Interdomain Contacts

Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.

Molecular Modeling Study on the Interaction Mechanism Between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.

LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1.

Membrane remodeling properties of the Parkinson's disease protein LRRK2

Electron Microscopy Structure of Dimeric Lrrk2 Reveals A Structural and Regulatory Role of the Cor Domain

Phosphorylation-dependent 14-3-3 Binding to LRRK2 is Impaired by Common Mutations of Familial Parkinson's Disease.

Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2

Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles Through Protein Interactions Mediated by Its C-Terminal WD40 Domain

Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2

Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism

Two Helices Control the Dynamic Crosstalk Between the Catalytic Domains of LRRK2

Misfolded protein propagation in an integrated computational model of structural network and <i>LRRK2</i> gene expression

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

Understanding the Pathogenicity of Parkin Catalytic Domain Mutants

Kinase Activity of Mutant LRRK2 Mediates Neuronal Toxicity

Correlation between Mutations in the LRRK2 and Parkinson′s Disease

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

The Parkinson's Disease-Associated Mutation LRRK2 G2385R Alters Mitochondrial Biogenesis Via the PGC-1α-TFAM Pathway.